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Abstract
Introduction: Occlusal splint therapy is a well-known method for the treatment of TMD. Muscle stretching and pain relief are effects of 
occlusal appliance. The aim of this study was to evaluate the plasma level of CGRP in patients with myofascial pain (RDC/TMD Ia) and 
myofascial pain with limited opening (RDC/TMD Ib) before and after muscle stretching with occlusal splint therapy. 
Material and methods: A randomised trial was performed including 35 subjects (males = 10, females = 25) in the experimental group 
and 30 subjects (males = 9, females = 21) in the control group. Blood samples were taken from the external jugular vein before and after 
30 days of occlusal splint therapy. Plasma levels of CGRP were measured with a Radio Immunoassay Kit (Phoenix Pharmaceuticals Inc.) 
and Cobra Series Auto-Gamma Counting System. 
Results: The results of the study demonstrated that CGRP concentrations were significantly higher after occlusal splint than before splint 
therapy: CGRP2 = 17.02 pg/mL (SD = 5.85), CGRP1 = 13.78 pg/mL (SD = 5.12), in the experimental group (p < 0.05). 
In the control group, there were no statistically significant changes in CGRP levels: CGRP1 = 14.5 pg/mL (SD = 4.87) to CGRP2 = 13.5 pg/
mL (SD = 4.63). In the experimental group, there was a statistically significant reduction in pain intensity, VAS1 = 5 (SD = 2.5) to VAS2 
= 1 (SD = 1.04) after splint therapy (p < 0.05). In the control group, there were no statistically significant changes in pain intensity: VAS1 
= 5 (SD = 2.3) to VAS2 = 4 (SD = 2.6), (p < 0.05). 
Conclusions: CGRP plays an important role in muscle blood flow, which is altered by changes in muscle length. Further in-
vestigation is needed to clarify the mechanism of muscle blood flow and the muscle healing process in patients with TMD. 
(Endokrynol Pol 2014; 65 (3): 217–222)
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Streszczenie
Wstęp: Szynoterapia jest popularną formą leczenia dysfunkcji układu ruchowego narządu żucia (DURNŻ). Głównymi jej efektami są 
zmiany napięcia mięśni oraz działanie przeciwbólowe. Celem pracy była ocena stężenia CGRP u pacjentów cierpiących z powodu bólu 
mięśniowo-powięziowego mięśni żucia (RDC/TMD Ia) oraz bólu mięśniowo-powięziowego z ograniczonym odwodzeniem żuchwy 
(RDC/TMD Ib) przed i po szynoterapii. 
Materiał i metody: Przeprowadzono randomizowane badanie kliniczne obejmujące 35 pacjentów z DURNŻ w grupie badanej: 10 męż-
czyzn oraz 25 kobiet oraz 30 pacjentów z DURNŻ w grupie kontrolnej: 9 mężczyzn i 21 kobiet. Materiał do badania pobierano z żyły 
szyjnej zewnętrznej przed oraz po 30 dniach szynoterapii. Do oceny stężenia CGRP zastosowano zestaw Radio Immunoassay Kit (firmy 
Phoenix Pharmaceuticals Inc.) oraz system Cobra Series Auto-Gamma Counting System. 
Wyniki: Uzyskane wyniki wskazują, że stężenia CGRP w badanej grupie był znacząco wyższy po niż przed szynoterapią: CGRP2 = 17,02 
pg/ml (SD = 5,85), CGRP1 = 13,78 pg/ml (SD = 5,12), (p < 0,05). W grupie kontrolnej nie odnotowano istotnych statystycznie zmian: przed 
i po szynoterapi: CGRP1 = 14.5 pg/ml (SD = 4,87), CGRP2 = 13,5 pg/ml (SD = 4,63). W grupie badanej zauważono statystycznie istotną 
redukcję natężenia bólu, VAS1 = 5 (SD = 2.5), VAS2 = 1 (SD = 1,04) (p < 0,05). W grupie kontrolnej nie wystąpiły istotne statystycznie 
zmiany w natężeniu bólu: VAS1 = 5 (SD = 2,3), VAS2 = 4 (SD = 2,6), (p < 0,05). 
Wnioski: Podsumowując, CGRP odgrywa istotną rolę w regulacji przepływu krwi przez mięśnie żucia. Perfuzja krwi przez 
tkankę mięśniową zmienia się wraz z długością mięśnia podczas szynoterapii. Niezbędne są dalsze badania, które wyja-
śnią mechanizm regulacji przepływu krwi przez mięśnie żucia oraz gojenia tkanki mięśniowej, u pacjentów z DURNŻ. 
(Endokrynol Pol 2014; 65 (3): 217–222)
Słowa kluczowe: CGRP (peptyd związany z genem kalcytoniny); dysfunkcja układu ruchowego narządu żucia; szyny okluzyjne 
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Introduction
Temporomandibular disorders (TMD) affect 70% of the 
population, but only 3–7% of these patients are aware 
of their disorder and seek treatment [1]. Occlusal splint 
therapy is a well-known and popular method for the 
treatment of TMD [8]. Many electromyography stud-
ies have revealed that occlusal splints reduce muscle 
tone and muscle pain [2–5, 7]. Only a few authors 
have studied the biochemical changes in the cranio-
mandibular tissues in TMD patients [6]. Recent data 
supports an important role for calcitonin gene-related 
peptide (CGRP) in deep tissue nociceptive process-
ing and tissue blood flow. In addition, peripheral 
and central sensitisation has been implicated in the 
pathology of TMD. Bruxism increases muscle tone in 
central nervous system excitation. The motor nucleus 
of the trigeminal nerve in the brainstem is influenced 
by emotional stress, and masticatory muscles are 
stimulated in an unconscious manner by thalamic 
and hypothalamic impulses. Shevel et al. analysed 
CGRP plasma changes in patients with migraines and 
reported that CGRP plays an important role in extrac-
ranial blood flow and migraine pathogenesis [9–11]. 
The continuum theory describes many similarities 
between migraines, tension-type headaches and TMD 
(Wolff ’s theory). At one end of the continuum theory 
is a pure vascular-pain migraine, and at the other 
end is muscle pain that is characteristic of TMD [12, 
13]. Electrical stimulation of trigeminal ganglion also 
elevated CGRP plasma levels in the external jugular 
vein in cats [14] and in patients with neuralgia during 
thermocoagulation of the trigeminal ganglion [15]. 
Similar trigeminal ganglion activation may occur as 
a result of myofascial pain. Durham et al. demon-
strated that botulinum neurotoxin A is effective in 
inhibiting CGRP release [11]. This neurotoxin is also 
very successful in treating TMD patients [26]. Goadsby 
has described elevated levels of CGRP in patients with 
cluster headaches, paroxysmal hemicranias and auto-
nomic cephalalgias [17, 18]. We have observed CGRP 
concentration changes in patients treated with oc-
clusal splints, in whom muscle stretching and muscle 
relaxation was performed. Muscle stretching was the 
effect of the occlusal appliance, which is one of many 
different occlusal splints used in TMD therapy [19]. 
The hypothesis was that an association exists between 
CGRP plasma level changes and splint treatment 
efficacy (pain reduction). CGRP sensory fibres are 
preferentially located in the arterial walls, and nerve 
fibres containing CGRP accompany small blood vessels 
in human cranial muscles. It has also been shown that 
the density of CGRP fibres around arteries is increased 
in persistently inflamed muscles (chronic myofascial 
pain Ia and Ib RDC/TMD- Research Diagnostic Crite-
ria/Temporomandibular Disorder) [17]. 
These findings indicate that ongoing activity in sen-
sory neurons in the cranial muscles may be reflected 
in changes of the plasma levels of neuropeptides in 
patients with myofascial pain. CGRP causes vasodila-
tion and a decrease in systemic vascular resistance, 
resulting in hypotension [19]. CGRP can be released 
antidromically, eliciting neurogenic inflammation [21]. 
CGRP also regulates bronchial smooth muscle tone in 
the human airway [21].
The aim of this study was to evaluate the plasma 
level of calcitonin gene-related peptide (CGRP) in 
patients with myofascial pain (RDC/TMD Ia) and 
myofascial pain with limited opening (RDC/TMD Ib) 
before and after muscle stretching with occlusal splint 
therapy. The results were compared to a control group. 
The study was designed to evaluate whether changes 
in CGRP levels were associated with pain reduction 
and muscle relaxation during occlusal splint treatment.
Material and methods 
A parallel group, randomised trial was performed 
including 120 patients. Of these, 48 patients were 
excluded because 40 of them did not meet inclusion 
criteria, three patients declined to participate, and five 
patients were treated with anticoagulants. Seventy-
two patients were allocated into one of two groups (by 
picking a colour card from an envelope). One patient 
did not accept the occlusal appliance, and six patients 
did not return for control visits. The experimental 
group consisted of 35 subjects (males = 10, females 
= 25), and the control group consisted of 30 subjects 
(males = 9, females = 21) aged 44–70 years (average = 
47 years). The patients were examined using the RDC/ 
/TMD clinical and physical examination form. One 
person enrolled participants in the study, and another 
dental practitioner assigned them to the interventions. 
The main eligibility criteria for the participants were 
a temporomandibular disorder-positive RDC/TMD 
examination for group Ia and Ib and patient agreement 
to participate in the experimental study. Exclusion 
criteria were primary headaches, ophthalmological, 
neurological, cardiovascular diseases, head trauma in 
the past six months, secondary headaches, trigeminal 
neuralgia, anticoagulation treatment and platelet or 
coagulation disorders. Myofascial pain was an indica-
tion for preparing occlusal appliances in both groups. 
Control subjects were given occlusal appliances 30 days 
after the second CGRP2 sample collection. We analysed 
plasma levels of neuropeptide CGRP with a Radio Im-
munoassay Kit (Phoenix Pharmaceuticals Inc.) using 
a Cobra Series Auto-Gamma Counting System. Samples 
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were collected before occlusal splint treatment (CGRP1) 
and after 30 days of splint therapy (CGRP2) in the ex-
perimental group. Blood samples in the control group 
were collected at the same time without any splint 
therapy. Blood samples were taken from the external 
jugular vein on the painful side during the clinic visit. 
If the myofascial pain was equal on both sides, we pre-
ferred the right jugular vein. Patients were in a supine 
position on a dental chair in the treatment room when 
the physician performed the venipuncture. The results 
were analysed with Statistica 7.0 for each group, and an 
ANOVA-derived pattern analysis was also performed. 
The study was approved by the Bioethical Commit-
tee of Silesian Medical University, document number 
KNW/0022/KB1/33/I/12 on 22.05.2012r.
Results
The results of the study demonstrated that plasma 
CGRP concentrations were significantly higher after 
occlusal splint therapy, CGRP2 = 17.02 pg/mL (SD = 
5.85), than before splint therapy, CGRP1 = 13.78 pg/mL 
(SD = 5.12), in the experimental group (p < 0.05) (Fig. 1). 
In the control group, there were no statistically signifi-
cant changes in CGRP plasma levels, with the average 
level changing from CGRP1 = 14.5 pg/mL (SD = 4.87) 
to CGRP2 = 13.5 pg/mL (SD = 4.63) (Fig. 2). The pain 
intensity was evaluated according to the 0-10 point VAS 
scale. In the experimental group, there was a statistically 
significant reduction in pain intensity, with the average 
pain intensity changing from VAS 1 = 5 (SD = 2.5) to 
VAS2 = 1 (SD = 1.04) after splint therapy (p < 0.05) 
(Fig. 3). In the control group, there were no statistically 
significant changes in pain intensity based on the VAS 
scale, with the average pain intensity changing from 
VAS1 = 5 (SD = 2.3) to VAS2 = 4 (SD = 2.6), (p < 0.05) 
(Fig. 4). The trial ended after one month, as planned. 
There were no complications or any unintended effects 
in either group. Patients were treated with relaxing 
splints for three months after the trial was finished. 
If any additional prosthodontic or orthodontic treat-
ment was needed, the patients were treated in our 
department. 
Discussion
In 1995, Appelgren et al. reported the important role of 
CGRP in TMD and other debilitating orofacial diseases 
[22]. Vause and Durham proposed that CGRP was re-
leased from neurons of the trigeminovascular system 
and could promote and maintain trigeminal ganglion 
inflammation, which mediates peripheral sensitisation 
and temporomandibular disorders [25]. We found el-
evated CGRP plasma levels that were accompanied by 
Figure 1. CGRP level changes before (CGRP1) and after 30 days of 
treatment (CGRP2) in patients treated with an occlusal appliance
Rycina 1. Zmiany stężenia CGRP przed (CGRP1) oraz po 30 
dniach szynoterapii(CGRP2)
Figure 2. CGRP level changes in control group patients before 
(CGRP1) and after 30 days of no treatment (CGRP2) 
Rycina 2. Zmiany stężenia CGRP u pacjentów w grupie 
kontrolnej przed (CGRP1) i po 30 dniach bez leczenia (CGRP2)
Figure 3. Pain VAS changes before (CGRP1) and after 30 days 
of treatment (CGRP2) in patients treated with occlusal appliance
Rycina 3. Natężenie bólu przed (CGRP1) i po 30 dniach 
szynoterapii (CGRP2) u pacjentów leczonych szyną okluzyjną
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pain relief in patients treated with occlusal splints after 
30 days of muscle relaxation. There were no statistically 
significant changes in the CGRP plasma level or VAS 
level in patients in the control group. After 30 days of 
occlusal splint therapy, there was a statistically signifi-
cant reduction in pain intensity based on the VAS scale 
in patients treated with occlusal splints, and patients’ 
health improved as well.
There are studies comparing CGRP levels in the 
external jugular vein and the radial or cubital vein [24, 
25]. Blood samples collected from the radial vein would 
most likely be less useful than those from the external 
jugular vein because of the lower peripheral CGRP 
levels. In 2000, Ashina and Bendtsen measured elevated 
CGRP levels in blood collected from the cubital vein 
[25]. According to a later study (2005) by Tvedskov and 
Ashina, there is no difference between CGRP levels in 
the cubital fossa and the external jugular vein in patients 
with migraines [26]. New and more sensitive methods 
of analysis are necessary to clarify whether the CGRP 
concentration in the radial vein is high enough to be 
detectable in TMD patients [25, 26]. Venipuncture was 
one of our trial limitations because the procedure was 
stressful for the patients and not every patient decided 
to participate in the trial. Another limitation was the 
short period of time between the collection of the first 
and second blood samples. The samples used for meas-
urements can only be frozen at –70°C for one month. 
In 1999, Parlapiano evaluated CGRP plasma levels and 
ET-1 plasma levels in normal subjects and reported 
that the mean plasma CGRP level was 42.8 pg/mL. 
The plasma concentration was measured using a com-
petitive radioimmunoassay kit (Peninsula Labs), but 
the authors did not mention which blood vessels the 
blood samples were collected from [27]. Elevated levels 
of CGRP were also analysed by Joyce et al., who found 
that in healthy patients, the level was 2.0 ± 0.3 pg/mL and 
that in patients with sepsis, the level was 14.9 ± 3.2 pg/mL 
[19]. These findings contribute to a decreased vascular 
resistance in dilatory states and increased cardiac out-
put in septic states. The same vascular dilatation may 
occur in masticatory muscles of patients with TMD. 
Most studies have analysed the nociceptive CGRP 
mechanism of action; however, few have studied the 
vasodilatory properties. Muscle pain causes release of 
neuropeptides, which initiate and maintain neurogenic 
inflammation. Peripheral and central sensitisation leads 
to hyperalgesia and allodynia. Cady et al. injected 
CGRP into the TMJ capsule of rats and observed the 
inflammation process and sensitisation [1]. Sato et al. 
studied CGRP-positive cells in synovial connective tis-
sues around blood vessels in TMJ and found the num-
ber to be significantly higher in the experimental group 
than in healthy volunteers. They concluded that CGRP 
may play an important role in the pain mechanism and 
that CGRP elevated levels may be correlated with joint 
pain. Wu et al. analysed CGRP expression in rats using 
an image analysis system and concluded that CGRP 
nerve fibres may be found in pathological TMJ tissues 
after emotional stress. Bick demonstrated that CGRP 
causes calcium mobilisation in skeletal muscle cells. 
High levels of CGRP caused continuous tetanus, which 
could be the reason for muscle-tension headaches. 
Bick conducted different studies with various aspects 
of muscle soreness, exercise and repair. Homonko ob-
served an increased number of CGRP+ motoneurons in 
muscles after physiological neuromuscular activity [28, 
29]. The exercise regimen may result in damage to the 
muscle tissue, thereby initiating repair and regenera-
tive mechanisms [29]. This repair process may be the 
reason for the elevated concentration of CGRP in our 
experimental group of patients with TMD. Jonhagen 
detected increased CGRP levels after eccentric exercise 
in healthy subjects, which may reflect tissue regenera-
tion [30]. Eccentric contraction can occur after muscles 
are stretched during contraction [31]. CGRP muscle 
levels were estimated in vivo by microdialysis followed 
by radioimmunoassay and were found to be increased 
a few days after eccentric exercise, and this may also be 
the reason for the elevated CGRP plasma levels in our 
experimental group of patients. The eccentric exercise 
performed in the Jonhagen study may be similar to the 
masseter and temporalis muscle exercises with occlusal 
splints in our experimental group [30]. According to 
Dessem et al., the masseter muscle has a limited ability 
to repair itself after injury and a tendency to undergo 
apoptosis [32]. Dessem also presented evidence that 
masticatory muscles do not adapt to repeated injury 
(bruxism), such as that occurring in hindlimb muscles; 
Figure 4. Pain VAS changes in control group patients before 
(CGRP1) and after 30 days of no treatment (CGRP2)
Rycina 4. Natężenie bólu przed (CGRP1) i po 30 dniach bez 
leczenia (CGRP2) 
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therefore, masticatory muscles are more susceptible to 
injuries and chronic muscle pain.
McDaniel noticed that blood flow in muscles is al-
tered by changes in muscle length, i.e. the longer and 
more relaxed the muscle is, the higher the blood flow 
[33]. Occlusal splints change the vertical dimension and 
stretch masseter and temporal muscles. The altered 
muscle length decreases muscle tone and produces mas-
ticatory muscle relaxation, which is probably the reason 
for increased muscular blood flow. These findings sug-
gest that CGRP may participate in muscle contraction 
and stretching. Cerebral blood vessels are innervated 
by sensory nerves that store several neurotransmit-
ters. In primary headaches, there is a clear association 
between head pain and the release of the neuropeptide 
CGRP [10, 20, 34, 35]. Durham and Cady reported that 
decreased amounts of CGRP were released from rat 
trigeminal ganglion cells after the administration of 
botulinum toxin type A [BTX-A] [11]. Muscle spasm 
may also be treated successfully with botulinum toxin 
type A by local muscle injection, as reported by Guarda-
Nardini in an investigation of its efficacy in reducing 
myofascial pain symptoms in bruxers [36]. Muscle 
stretching with occlusal splints increases CGRP release 
from the trigeminovascular system, but BTX-A produces 
muscle paralysis and decreases the CGRP concentra-
tion. An interesting observation in our study is that dur-
ing the time of elevated CGRP plasma concentration, 
there was a negative correlation between the VAS scale 
and the CGRP plasma level concentration. A similar 
situation was observed by Ashina, who indicated that 
ongoing activity in sensory neurons in cranial muscles 
may result in plasma CGRP level changes in patients 
with chronic headache. Eight patients had higher CGRP 
plasma levels in the delayed headache-free period. 
However, a small number of patients were enrolled in 
this study, and the CGRP plasma levels in the cranial 
and peripheral circulation may be undetectable [6]. 
Eccentric muscle contraction and rapid stretching pro-
duces scattered myofibres and intramuscular plasma 
extravasation [31]. CGRP vasodilates blood vessels in 
muscle tissue and mediates neurogenic inflammation. 
In his study, Donnerer noted an important regulatory 
function of neuropeptides such as CGRP and substance 
P in healing processes [37]. 
Conclusions 
CGRP neuropeptide is most likely also implicated in 
muscle healing and may serve multiple functions in-
cluding muscle repair. This study shows that CGRP is 
involved in muscle contractility and the myofibre repair 
process in patients with TMD. Further investigation is 
necessary in this field.
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